Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Next Stop for Nokia Corp (ADR) Stock: $5 a Share!

By Chris Lau, InvestorPlace Contributor

Nokia (NOK) reported a solid quarter, but investors ignored the potential for more IP and brand revenue and network demand rebounding.

Watch User Engagement When Twitter Inc (TWTR) Stock Reports Earnings

By Chris Lau, InvestorPlace Contributor

Twitter (TWTR) is either a buyout target or fairly valued and moving nowhere. The earnings report on Feb 9 may give the stock a lift.

3 Beaten Biotech Stocks That Are Set to Rebound

By Chris Lau, InvestorPlace Contributor

Horizon Pharma (HZNP), Synergy Pharmaceuticals (SGYP) and Keryx Biopharmaceuticals (KERX) are down sharply, but are set to rebound.

Why Valeant Pharmaceuticals Intl Inc (VRX) Stock Will Finally Stabilize

By Chris Lau, InvestorPlace Contributor

Valeant Pharmaceuticals (VRX) is finally getting its house in order. Don't expect VRX stock to explode, but it will get a lift.

Twitter Inc (TWTR) Sells Fabric, So Where Is the Takeover Offer?

By Chris Lau, InvestorPlace Contributor

Twitter (TWTR) looked ripe for getting bought out last year, so after selling Fabric to Alphabet, when is the bid for TWTR stock coming?

Load More